HNWAG
XFOR icon

High Net Worth Advisory Group’s X4 Pharmaceuticals XFOR Stock Holding History

High Net Worth Advisory Group’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-37
Closed -$1.09K – 589
2022
Q4 		$1.09K Hold
37
– – ﹤0.01% 592
2022
Q3 		$2K Hold
37
– – ﹤0.01% 640
2022
Q2 		$1K Hold
37
– – ﹤0.01% 663
2022
Q1 		$2K Hold
37
– – ﹤0.01% 648
2021
Q4 		$3K Buy
+37
New +$4.68K ﹤0.01% 640

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TLP
Tri Locum Partners New York $813M AUM 101.01% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

High Net Worth Advisory Group's XFOR Position: Q1 2023 in Review

High Net Worth Advisory Group sold out of X4 Pharmaceuticals (XFOR) in Q1 2023, closing a stake of 37 shares — an estimated $1.09K sold.

High Net Worth Advisory Group first reported a position in XFOR in Q4 2021 and held it in 5 quarters. The position peaked at $3K in Q4 2021. 56 funds tracked by Wall St. Rank hold XFOR as of Q1 2023.

  • High Net Worth Advisory Group reported no remaining X4 Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • High Net Worth Advisory Group sold 37 X4 Pharmaceuticals shares in Q1 2023, an estimated $1.09K.
  • High Net Worth Advisory Group first reported a position in X4 Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • High Net Worth Advisory Group's X4 Pharmaceuticals position peaked at $3K in Q4 2021.
  • 56 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2023.

Based on High Net Worth Advisory Group's 13F filing for Q1 2023, filed 20 Apr 2023.